Literature DB >> 34160745

MiR-137 inhibits the proliferation, invasion and migration of glioma via targeting to regulate EZH2.

Jingshun Gu1, Juntong Wang1, Aiwu You1, Jun Li1, Yuyan Zhang1, Guomin Rao2, Xuehua Ge1, Kun Zhang1, Xuan Liu3, Dongchun Wang4.   

Abstract

BACKGROUND: Gliomas are common malignant tumors in the nervous system, known for poor prognosis and low survival rate.
OBJECTIVE: This study aims to explore functions of miR-137 in glioma progression and identify messenger RNAs (mRNA) regulated by miR-137, which provides new ideas for further exploration of glioma therapeutic targets.
METHODS: Gene expression data were downloaded from the Cancer Genome Atlas database, and abnormally expressed miRNAs and mRNAs in glioma were analyzed. The expression of genes in 20 pairs of clinical tissue samples and glioma cell lines were detected through qRT-PCR, and the expression of proteins was detected through Western blot. Changes in cell proliferative level after transfection were detected via CCK8 assay, and changes in cell migratory and invasive abilities were detected by Transwell assay. Besides, dual-luciferase reporter assay was employed to testify binding relationship between two genes.
RESULTS: Our study found that miR-137 was significantly and lowly expressed in glioma tissue and cell lines, and the prognoses of glioma patients with highly expressed miR-137 were more optimistic. Overexpressed miR-137 could remarkably inhibit proliferative, invasive and migratory abilities of glioma cells U87, while transfection of miR-137 inhibitor presented an opposite effect. Additionally, EZH2 was a direct target of miR-137 and overexpressed EZH2 effectively reversed the effect of miR-137 on glioma proliferation and migration.
CONCLUSIONS: Our study found that miR-137 could suppress the proliferation, invasion and migration of glioma cells through regulating the expression of EZH2. So far, we have found a novel regulatory pair that influences glioma progression, providing a basis for further development of new therapeutic strategies.
© 2021. The Genetics Society of Korea.

Entities:  

Keywords:  EZH2; Glioma; Invasion; Migration; Proliferation; miR-137

Mesh:

Substances:

Year:  2021        PMID: 34160745     DOI: 10.1007/s13258-021-01117-9

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  4 in total

1.  Long non-coding RNA XIST exerts oncogenic functions in human glioma by targeting miR-137.

Authors:  Zong Wang; Jiangwei Yuan; Li Li; Yang Yang; Xuchang Xu; Ying Wang
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

2.  miR-137 suppresses proliferation, migration and invasion of colon cancer cell lines by targeting TCF4.

Authors:  Wei-Ping Bi; Min Xia; Xin-Jian Wang
Journal:  Oncol Lett       Date:  2018-03-28       Impact factor: 2.967

3.  MiR-137 and its target TGFA modulate cell growth and tumorigenesis of non-small cell lung cancer.

Authors:  X Liu; L Chen; X-D Tian; T Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-02       Impact factor: 3.507

4.  Role of the microRNA 181 family in glioma development.

Authors:  Liu Yang; Yueyun Ma; Yijuan Xin; Ruobin Han; Rui Li; Xiaoke Hao
Journal:  Mol Med Rep       Date:  2017-10-26       Impact factor: 2.952

  4 in total
  2 in total

1.  Procollagen C-protease enhancer protein is a prognostic factor for glioma and promotes glioma development by regulating multiple tumor-related pathways and immune microenvironment.

Authors:  Zijun Zhao; Jiahui Zhao; Zairan Wang; Yue Wu; Zhanzhan Zhang; Zihan Song; Jihao Miao; Boheng Liu; Shiyang Zhang; Boyu Sun; Zongmao Zhao
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

2.  CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway.

Authors:  Qianxu Jin; Jiahui Zhao; Zijun Zhao; Shiyang Zhang; Zhimin Sun; Yunpeng Shi; Hongshan Yan; Yizheng Wang; Liping Liu; Zongmao Zhao
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.